UNSPSC 51141548: Atolide

This classification denotes an anticonvulsant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OBN5I4B08W. European Medicines Agency schedules Atolide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05599MIG. Atolide generally arises in the molecular formula C18H23N3O.

The term ATOLIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, no. 10, 1968, list 8.) ATOLIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule atolide under HS 29242995 and SITC 51479. As of Q4 2014, ATOLIDE remains the US FDA Preferred Term for this commodity. Atolide bears US NLM identifiers UMLS ID C2698194 and NCI Concept Code C77997. SMILES: O=C(NC1C(CC(N(CC)CC)CC1)C)C1C(N)CCCC1.

UNSPSC 51141548 Atolide is a Commodity code under which state and local governments procure pharmaceutical products, including naloxone, safe drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter medications distributed through established wholesaler networks and direct-to-manufacturer programs. Recent solicitations reveal that issuing bodies range from county health departments and state health and human services agencies to cooperative purchasing alliances spanning multiple states. Seminole County, Florida, for example, recently issued an IFB seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding for community health initiatives, while the Texas Health and Human Services Commission posted an RFI to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program designed to improve prescription fulfillment efficiency and cost management outside traditional pharmacy benefit manager and group purchasing organization channels.

Geographic activity spans at least Florida, Texas, and the upper Midwest, with the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) — administered by the Minnesota Department of Administration's Office of State Procurement — issuing a major RFP in January 2026 for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local government facilities, including Oregon, with proposals due March 26, 2026. The MMCAP procurement requires vendors to supply products through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co.), certify cGMP and Drug Supply Chain Security Act compliance, maintain relationships with at least two of the three authorized wholesalers, and pay a 3 percent administrative fee on all contract purchases. Vendors awarded under the MMCAP contract will be provided to wholesalers by May 15, 2026, with agreements effective July 1, 2026, and a two-year term with optional extensions at MMCAP's discretion.